Literature DB >> 23992531

Drug-induced Brugada syndrome by noncardiac agents.

Konstantinos P Letsas1, Charalampos Kavvouras, George Kollias, Spyridon Tsikrikas, Panagiotis Korantzopoulos, Michalis Efremidis, Antonios Sideris.   

Abstract

Drug-induced Brugada syndrome (BrS) represents a great challenge for the prescribing clinicians as well as for those involved in the development of novel pharmaceuticals and in the regulatory bodies responsible with monitoring drug safety. Apart from well-known cardiac agents (mainly Class I antiarrhythmics), an increasing number of noncardiac agents, including psychotropic and anesthetic drugs, have been shown to induce the characteristic Brugada electrocardiogram pattern predisposing to fatal ventricular arrhythmias. Up to now, both repolarization and depolarization abnormalities are thought to be related to the development of ventricular fibrillation in BrS patients. This review highlights the mechanisms and the noncardiac medical agents that unmask a genetic predisposition to BrS. ©2013, The Authors. Journal compilation ©2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  Brugada syndrome; drugs; sudden cardiac death

Mesh:

Substances:

Year:  2013        PMID: 23992531     DOI: 10.1111/pace.12234

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  3 in total

1.  Lacosamide induced Brugada I morphology in the setting of septicemia: A case report.

Authors:  Robert Goodnough; Adina Badea; Curtis Geier; Kara L Lynch; Kathy T LeSaint
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

2.  Labor Analgesia in Brugada Syndrome and the Importance of Contingency Planning.

Authors:  Shayla Mena; Ana Costa; Michelle DeLemos; Joy Schabel; Morgane Factor
Journal:  Case Rep Anesthesiol       Date:  2022-07-15

Review 3.  Role of Provocable Brugada ECG Pattern in The Correct Risk Stratification for Major Arrhythmic Events.

Authors:  Nicolò Martini; Martina Testolina; Gian Luca Toffanin; Rocco Arancio; Luca De Mattia; Sergio Cannas; Giovanni Morani; Bortolo Martini
Journal:  J Clin Med       Date:  2021-03-02       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.